PPARγ activation reduces visceral and hepatic fat, while inducing maturation of insulin sensitive subcutaneous fat, as demonstrated with pioglitazone, a PPARγ agonist approved for T2D; in contrast, weight gain from diet failure increased visceral and hepatic fat44,45. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.